Phase 2 Study of the Safety and Antitumor Activity of Apalutamide in the High-risk Nonmetastatic Castration-resistant Prostate Cancer - Charles Ryan

Journal Club: Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
European Urology

Charles Ryan, MD discusses the androgen receptor antagonist apalutamide was safe in patients with high-risk nonmetastatic castration-resistant prostate cancer and, based on durable prostate-specific antigen responses and disease control, exhibited robust activity. These results support continued clinical development of apalutamide in future efficacy and safety studies

Additonal resources:

Biography: 
Charles J. Ryan, MD is Professor of Clinical Medicine and Urology and the Clinical Program Leader for Genitourinary Medical Oncology at the UCSF Helen Diller Family Comprehensive Cancer Center. He received his MD from the University of Wisconsin in Madison and completed his residency in internal medicine at the University of Wisconsin Hospital and Clinics, where he also served as Chief Resident. He completed a fellowship in medical oncology in the Department of Medicine at Memorial Sloan-Kettering Cancer Center and the Joan and Sanford I. Weill Medical College of Cornell University in New York

Professor of Clinical Medicine and Urology; Program Leader, Genitourinary Medical Oncology; Associate Director for Clinical Sciences, UCSF Helen Diller Family Comprehensive Cancer Centerpro